2015 life sciences outlook
United States

Despite their considerable size and resources, U.S. life sciences companies — like their peers in Europe and elsewhere — operate in a dynamic environment that presents numerous challenges to revenue and market share growth. Among the set of intertwined, critical issues that companies face in 2015, six rise to the top:

1. Market reconfiguration and consolidation
Expiring patents, shorter product life cycles, formulary coverage challenges, changing commercial practices, growth in new markets, and value-based reimbursements are all driving the need for organizations to reassess strategies, reconfigure business models, and explore potential mergers and acquisitions (M&A) opportunities.

Increasingly, life sciences companies are searching for the right scale in today’s competitive environment. Some are focusing on pure plays in a given segment or therapeutic area; others are building out capabilities by acquiring and managing a large portfolio of businesses across a range of areas. Each of these approaches is resulting in an unprecedented level of deal-making in the form of mergers, acquisitions, joint ventures, divestitures, and licensing.

---

1. IBISWorld Industry Report 32541a, Brand Name Pharmaceutical Manufacturing in the US, August 2014
2. IBISWorld Industry Report 32541b, Generic Pharmaceutical Manufacturing in the US, July 2014
3. IBISWorld Industry Report NN001, Biotechnology in the US, November 2014
4. IBISWorld Industry Report 33451b, Medical Device Manufacturing in the US, October 2014
5. IBISWorld Industry Report 33911a, Medical Instrument & Supply Manufacturing in the US, September 2014
As decision-making increasingly moves from individual providers to large health systems and health plans, life sciences companies will have to think differently about who their customers are and how to best engage with them. They will need to shift from business-to-consumer (B2C)-like sales and marketing to health care providers as individuals and move more toward business-to-business (B2B)-like sales and marketing to institutional decision makers.

Looking ahead, market and economic conditions are expected to continue to create a favorable climate for life sciences M&A. If properly planned by company boards and executives, done for the right strategic reasons, and based on solid roadmaps and frameworks, M&A may be an effective option for business growth and sustainability in 2015.

2. Pricing pressures

Americans pay more for prescription drugs than consumers from any other country.11 The federal government is not permitted by law to negotiate with drug manufacturers to obtain more favorable prices; however, through legislative and regulatory activity, it is working to control pharmaceutical costs by spurring competition and going after industry anti-competitive practices (e.g., “pay-to-delay” payments). The Accountable Care Act (ACA) reforms include a shortened pathway for regulatory approval of biosimilars, generic versions of off-patent biotech drugs (although the legislation also lengthened the patent protection period for biotech drugs to 10 years).13

In addition, emerging markets are fueling the growth of local companies that are expected to shift the U.S.-centric “skew” of the global competitive landscape and open up new M&A opportunities for U.S. companies.

M&A activity taking place among health care providers, health plans, and downstream subsectors (e.g., distributors, pharmacies, pharmacy benefits managers) also has important implications for the life sciences industry. First, M&A could shift negotiating power to these downstream players. Second, it could disintermediate life sciences companies from patients and physicians as these consolidating and converging players invest in a broader set of offerings for them. On the flip side, M&A creates potential partnership opportunities for life sciences companies looking to innovate on patient and physician engagement.

As decision-making increasingly moves from individual providers to large health systems and health plans, life sciences companies will have to think differently about who their customers are and how to best engage with them. They will need to shift from business-to-consumer (B2C)-like sales and marketing to health care providers as individuals and move more toward business-to-business (B2B)-like sales and marketing to institutional decision makers.

Looking ahead, market and economic conditions are expected to continue to create a favorable climate for life sciences M&A. If properly planned by company boards and executives, done for the right strategic reasons, and based on solid roadmaps and frameworks, M&A may be an effective option for business growth and sustainability in 2015.

2. Pricing pressures

Americans pay more for prescription drugs than consumers from any other country. The federal government is not permitted by law to negotiate with drug manufacturers to obtain more favorable prices; however, through legislative and regulatory activity, it is working to control pharmaceutical costs by spurring competition and going after industry anti-competitive practices (e.g., “pay-to-delay” payments). The Accountable Care Act (ACA) reforms include a shortened pathway for regulatory approval of biosimilars, generic versions of off-patent biotech drugs (although the legislation also lengthened the patent protection period for biotech drugs to 10 years).

In addition, emerging markets are fueling the growth of local companies that are expected to shift the U.S.-centric “skew” of the global competitive landscape and open up new M&A opportunities for U.S. companies.

M&A activity taking place among health care providers, health plans, and downstream subsectors (e.g., distributors, pharmacies, pharmacy benefits managers) also has important implications for the life sciences industry. First, M&A could shift negotiating power to these downstream players. Second, it could disintermediate life sciences companies from patients and physicians as these consolidating and converging players invest in a broader set of offerings for them. On the flip side, M&A creates potential partnership opportunities for life sciences companies looking to innovate on patient and physician engagement.
The ACA also includes a 2.3 percent medical device excise tax, which is likely to put pressure on device prices. Given the mid-term election results, however, we could see Congress try to appeal this tax, even though cutting provisions that raise revenue would probably need to be paired with an offset to keep the effect on the budget deficit neutral. Finding such an offset might be politically challenging.

U.S. health plans are increasing their efforts to contain pharmaceutical costs, using a variety of methods including formularies (lists of medicines included or excluded for insurance coverage) and tiered co-payment schemes that require consumers to pay more out-of-pocket (OOP) for brand-name drugs than for generics. Health plans have become more stringent in their criteria for awarding coverage and reimbursement benefits for medtech products, as well.

Hospitals are also coming to the negotiating table more prepared than ever to secure favorable pricing — hiring specialists such as chief procurement officers and MBAs to manage the process and using value analysis committees or teams of clinical experts and administrative staff to make purchasing decisions. Pharmaceutical and medtech companies will need to be equally prepared.

3. Health reform and the shift to value

U.S. health reform is shining a spotlight on the shift from volume- to value-based care. In response, the life sciences industry will increasingly need to use real-world evidence and emphasize a product’s clinical, safety, and economic impact (e.g., comparative effectiveness) to better demonstrate and communicate drug and device prices with respect to their true value. That value should be compared to the next-best alternative inclusive of effectiveness rates, side effects, tolerability, and adjunct services such as programs to support better adherence. So while the price of a new treatment may appear high, if it is curative and replaces a treatment that is taken over a longer period with many doses and modest effectiveness, then the value is seen in a new light.

Companies will have to revisit the types of data they are generating from their clinical trials and competitive comparisons to ensure they are providing the evidence needed to demonstrate the types of value that align with each stakeholder’s expectations. For example, collecting and analyzing data that show how a medical technology outperforms its competitors in increasing hospital revenue, improving quality of care, or reducing overall health care system costs can be extremely valuable. These are the factors health plans and providers consider when evaluating the price of a product — the inputs that go into a more value-based pricing approach.

4. R&D productivity

A recent Deloitte and Thomson Reuters study of 12 large global life sciences companies found that their expected return on late-stage pipeline projects has declined across four years, to 4.8 percent in 2013 from 10.5 percent in 2010. Along with that, the cost to develop and launch a new medicine has increased 18 percent, to $1.3 billion.

In another sobering development, medtech manufacturing received steadily increasing venture capital investments from 2001 to 2009; however, investment peaked in 2009 at 13 percent of total health care venture capital dollars and has steadily declined since. The reduction in venture capital support for these innovations poses a risk to medtech companies’ ability to address future unmet clinical needs and to create substantial future demand for their products.
To combat declining R&D productivity, life sciences companies will need to increase efficiency, reduce costs, and maximize the commercial value of their investments. A few companies already are improving productivity within their drug pipelines — the line-up of diabetes and cancer drugs in late-stage development is extensive, and suggests that treatment breakthroughs may be imminent — by employing a variety of approaches, many of them complementary. In addition, innovating in specialty (versus primary care) therapeutic areas (TAs) may drive considerable pharmaceutical revenue growth in coming years. Specialty TA markets have lower patient volumes but greater unmet need, which supports high drug prices.

In medtech, some companies are shifting to more cross-functional development teams that integrate R&D, marketing, engineering, and other disciplines. Such teams more effectively connect customer insights with the biodesign process for product development. Medtech companies also are looking for ways to wrap health care services (e.g., cellular therapy) around their products.

Some biopharmaceutical companies are moving to M&A and open innovation models as a way to help overcome their organic productivity challenges. In “open innovation” models, multiple parties pool their risks, intellectual property, resources, and costs in pursuit of developing novel products and services. The resulting rewards are shared with the network.

5. Disruptive technologies

Life sciences companies should look to other industries and non-traditional players for disruptive technologies that could be applied to health care and foster product innovation, market expansion, and revenue growth. The proliferation of digital technology has dramatically increased the amount of information available to patients, putting more power in their hands. This makes patient engagement and patient experience a more important lever for life sciences companies, especially in light of downstream consolidation in the ecosystem.

For example, mobile health (mHealth) is expected to be a valuable partner in health care’s shift toward a patient-centered, value-based delivery model. mHealth has the potential to improve workplace efficiencies, increase patient safety, better coordinate care, facilitate payments, and engage patients.

Additive manufacturing (AM), often referred to as “3D printing,” also has disruptive potential in health care. The prospective benefits of AM are numerous — it can spur additional innovation, improve patient access to life-saving devices, simplify and accelerate the supply chain and production process, and achieve considerable savings. The medtech industry already stands at the forefront of this transformative change — medical applications account for about one-sixth of AM market revenues.

Finally, Artificial Intelligence, through exponential increases in data, computing power, connectivity, miniaturization of hardware, and advanced software capabilities at lower costs will rapidly accelerate the development of next-generation “smart” medtech devices and could cause profound disruption in the way health care is delivered in the future.

6. Risk, regulations, and compliance

U.S. life sciences companies operating in today’s global marketplace are at increasing risk of product safety issues, security and privacy breaches, intellectual property (IP) disputes, whistleblower complaints, and corruption incidents, each of which may result in financial and reputational damage. Concurrently, the U.S. and other governments are tightening regulations to address these risks and working more collaboratively to enforce them. Among important developments are calls for greater transparency in life sciences companies’ business and clinical operations — executive pay, financial information accuracy, manufacturing processes, transfers of value to health care practitioners and institutions as well as clinical trial quality.


THE ECONOMIST INTELLIGENCE UNIT

“Open innovation” models, multiple parties pool their risks, intellectual property, resources, and costs in pursuit of developing novel products and services. The resulting rewards are shared with the network.

5. Disruptive technologies

Life sciences companies should look to other industries and non-traditional players for disruptive technologies that could be applied to health care and foster product innovation, market expansion, and revenue growth. The proliferation of digital technology has dramatically increased the amount of information available to patients, putting more power in their hands. This makes patient engagement and patient experience a more important lever for life sciences companies, especially in light of downstream consolidation in the ecosystem.

For example, mobile health (mHealth) is expected to be a valuable partner in health care’s shift toward a patient-centered, value-based delivery model. mHealth has the potential to improve workplace efficiencies, increase patient safety, better coordinate care, facilitate payments, and engage patients.

Additive manufacturing (AM), often referred to as “3D printing,” also has disruptive potential in health care. The prospective benefits of AM are numerous — it can spur additional innovation, improve patient access to life-saving devices, simplify and accelerate the supply chain and production process, and achieve considerable savings. The medtech industry already stands at the forefront of this transformative change — medical applications account for about one-sixth of AM market revenues.

Finally, Artificial Intelligence, through exponential increases in data, computing power, connectivity, miniaturization of hardware, and advanced software capabilities at lower costs will rapidly accelerate the development of next-generation “smart” medtech devices and could cause profound disruption in the way health care is delivered in the future.

6. Risk, regulations, and compliance

U.S. life sciences companies operating in today’s global marketplace are at increasing risk of product safety issues, security and privacy breaches, intellectual property (IP) disputes, whistleblower complaints, and corruption incidents, each of which may result in financial and reputational damage. Concurrently, the U.S. and other governments are tightening regulations to address these risks and working more collaboratively to enforce them. Among important developments are calls for greater transparency in life sciences companies’ business and clinical operations — executive pay, financial information accuracy, manufacturing processes, transfers of value to health care practitioners and institutions as well as clinical trial quality. Under the ACA, for instance, pharmaceutical companies have to declare all payments to physicians.

In 2015 patient safety and data transparency will continue as focus areas for regulatory scrutiny and enforcement. For example, oversight has increased dramatically in the form of stringent demands for product data. The FDA recently instituted the Global Unique Device Identification Database (GUDID) to collect substantial volumes of manufacturing and registration information. Lengthy product approvals also remain an issue. The FDA review process for medtech companies is almost twice as long as that of its European counterpart, the European Medicines Agency. It takes companies six months on average to get 510(k) approval in the U.S. compared to three months in Europe. However, with generic pharmaceutical products, the FDA is making strides in the form of new guidance documents to improve the submission and approval process.

U.S. regulators also appear to be doing some “housekeeping” — making an effort to revisit old issues and bring them to closure (e.g., old guidance, draft rules, proposed rules). Meanwhile, agencies in other countries are increasing their regulatory rigor, and in emerging markets especially, their sophistication is increasing. The FDA used to be the gold standard, but now other agencies are matching or even surpassing the FDA. Life sciences companies can no longer assume that if they pass the FDA’s requirements, that they will have no problem passing other agencies’ requirements. Moving forward, organizations will need to cost-effectively address regulatory requirements that impact their strategic objectives at home and abroad.

Moving forward
As the health care industry shifts and transforms so, too, must the life sciences sector. In 2015, this may require companies to recalibrate business models and research priorities, and retool commercial practices to better articulate their value proposition. In addition, companies increasingly will need to use real-world evidence to demonstrate a product’s clinical, safety, and economic impact (e.g., comparative effectiveness), and robust data analytics to improve marketing strategies and effectiveness. They should consider M&A transactions to scale up within particular areas of specialization and exit others, and expand into new markets. Organizations also should engage in more proactive risk management and regulatory compliance.

In another key focus area, life sciences companies could improve R&D efficiency, diversify risks and costs, and use their human capital better by employing open innovation and other novel development approaches — for example, hosting companies on site or establishing innovation centers that incubate 30-40 companies to broaden future possibilities. In pursuit of innovative new products, they should look to develop patient-centric suites/portfolios of products and services to improve the overall health of their customers. For example, there is growing interest in wearable technologies and sensors to monitor vital signs; digital medicines such as ingestible smart pills with microchips; and novel drug delivery systems.

In essence, U.S. life sciences companies in 2015 should focus on areas in which they excel, improve areas that are important to achieving their goals, and let go of elements that might be holding them back.

Many U.S. life sciences companies are rethinking their business models and go-to-market approaches, given the challenges of an evolving, consolidating, and converging health care landscape.

To learn more about the global trends and issues impacting the life sciences sector, please visit our 2015 global life sciences sector outlook at www.deloitte.com/2015lifesciencesoutlook.